COGNANO Inc. is pleased to announce its collaboration with SEPIQ, a non-profit consortium dedicated to unraveling the complexities of life through antibody big data. As part of this partnership, COGNANO will provide its vast proprietary antibody datasets to support SEPIQ’s mission.
https://sepiq.uk/
Revolutionizing the Paradigm of Antibody Drug Discovery
Traditionally, antibody research has focused on identifying antibodies effective against specific diseases and optimizing their quality. However, fully understanding the fundamental mechanisms—why and how an antibody binds to a pathogen (antigen)—as digital data has remained a significant challenge.
SEPIQ is an international project aiming to decode these "intermolecular interactions" through the power of big data. Sharing this vision, COGNANO will provide large-scale, labeled antibody data meticulously constructed through our unique technology.
Decoding Structure from Sequence: An Inverse Approach
The scale of the data provided is unprecedented, defying conventional standards. By providing "labeled data" (pairs of antibodies and antigens) on a scale never before seen, we enable a breakthrough in structural biology. With such massive datasets, it becomes possible to understand the "shape" (structure) of an antigen with high precision, simply by analyzing the "sequence" (blueprint) of the antibody—effectively working in reverse.
A Vision for the Future
By proving and promoting this logic within the academic framework of SEPIQ, we aim to dramatically streamline the drug discovery process. This will pave the way for novel approaches to previously untreatable diseases.
COGNANO remains committed to integrating original biotechnology with digital innovation to contribute to the advancement of next-generation medicine and science.